Merck and Moderna maintain a decade-long collaboration on personalized mRNA cancer vaccines, most recently reinforced by positive Phase 3 INTerpath-001 data in August 2026 that drove sharp share price gains for both firms without any indication of broader corporate combination. Their existing licensing and profit-sharing structure on intismeran autogene allows shared upside on Keytruda combinations while preserving operational independence amid Keytruda patent considerations and Moderna’s post-COVID revenue shift. Recent Merck acquisitions, such as Terns Pharmaceuticals, have targeted pipeline assets rather than platform partners, underscoring a preference for targeted deals over full-scale mergers. With no regulatory filings, analyst reports, or management commentary signaling M&A discussions through early September 2026, trader consensus reflects the low likelihood of an announced transaction this year; tail risks remain limited to abrupt strategic pivots from major clinical setbacks or macroeconomic pressures.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于是
1% 概率
最新
最新
2026-12-31
是
1% 概率
最新
最新
2026-12-31
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-long collaboration on personalized mRNA cancer vaccines, most recently reinforced by positive Phase 3 INTerpath-001 data in August 2026 that drove sharp share price gains for both firms without any indication of broader corporate combination. Their existing licensing and profit-sharing structure on intismeran autogene allows shared upside on Keytruda combinations while preserving operational independence amid Keytruda patent considerations and Moderna’s post-COVID revenue shift. Recent Merck acquisitions, such as Terns Pharmaceuticals, have targeted pipeline assets rather than platform partners, underscoring a preference for targeted deals over full-scale mergers. With no regulatory filings, analyst reports, or management commentary signaling M&A discussions through early September 2026, trader consensus reflects the low likelihood of an announced transaction this year; tail risks remain limited to abrupt strategic pivots from major clinical setbacks or macroeconomic pressures.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
市场开放时间： Aug 19, 2026, 3:58 PM ET
交易量
$425结束日期
2027-01-01市场开放时间
Aug 19, 2026, 3:58 PM ETThis market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-long collaboration on personalized mRNA cancer vaccines, most recently reinforced by positive Phase 3 INTerpath-001 data in August 2026 that drove sharp share price gains for both firms without any indication of broader corporate combination. Their existing licensing and profit-sharing structure on intismeran autogene allows shared upside on Keytruda combinations while preserving operational independence amid Keytruda patent considerations and Moderna’s post-COVID revenue shift. Recent Merck acquisitions, such as Terns Pharmaceuticals, have targeted pipeline assets rather than platform partners, underscoring a preference for targeted deals over full-scale mergers. With no regulatory filings, analyst reports, or management commentary signaling M&A discussions through early September 2026, trader consensus reflects the low likelihood of an announced transaction this year; tail risks remain limited to abrupt strategic pivots from major clinical setbacks or macroeconomic pressures.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
交易量
$425结束日期
2027-01-01市场开放时间
Aug 19, 2026, 3:58 PM ETMerck and Moderna maintain a decade-long collaboration on personalized mRNA cancer vaccines, most recently reinforced by positive Phase 3 INTerpath-001 data in August 2026 that drove sharp share price gains for both firms without any indication of broader corporate combination. Their existing licensing and profit-sharing structure on intismeran autogene allows shared upside on Keytruda combinations while preserving operational independence amid Keytruda patent considerations and Moderna’s post-COVID revenue shift. Recent Merck acquisitions, such as Terns Pharmaceuticals, have targeted pipeline assets rather than platform partners, underscoring a preference for targeted deals over full-scale mergers. With no regulatory filings, analyst reports, or management commentary signaling M&A discussions through early September 2026, trader consensus reflects the low likelihood of an announced transaction this year; tail risks remain limited to abrupt strategic pivots from major clinical setbacks or macroeconomic pressures.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题